Skip to main content
. 2021 Feb 25;11:4728. doi: 10.1038/s41598-021-83928-0

Figure 3.

Figure 3

Impact of oesophageal reflux disease and prior PPI-treatment on PVI safety outcome. (A) PVI-associated mediastinal oedema were significantly more frequently detected in patients with pre-existing erosive oesophageal reflux disease compared to non-reflux patients (p = 0.041). Shown is the number of patients with or without mediastinal oedema after PVI. (B) Patients with constant PPI medication prior to PVI significantly suffered less frequently from erosive oesophageal reflux disease, assessed directly prior to PVI by EDG, compared to patients without prior constant PPI intake (p = 0.049). Shown is the number of patients with or without erosive oesophageal reflux prior to PVI. (C) In patients with constant PPI-treatment prior to PVI, PVI-associated mediastinal oedema were significantly less frequently observed by post-interventional endosonography (p = 0.036). Shown is the number of patients with or without mediastinal oedema after PVI. EGD, oesophagogastroduodenoscopy; PPI, proton pump inhibitor; PVI, pulmonary vein isolation.